Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
Date:4/14/2008

CALGARY, April 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced cancers including head and neck, melanoma, lung and ovarian.

"The preliminary results from this combination trial are very encouraging," said Dr. Brad Thompson, President and CEO of Oncolytics. "This study was the first to begin examining the use of REOLYSIN(R) with drug combinations that are used in first or second line therapy."

The principal investigators are Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, and Dr. Geoff Hall of St. James's Hospital in Leeds, U.K.

The trial (REO 011) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every three weeks. Standard dosages of paclitaxel and carboplatin were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further 12 patients at the maximum dosage of REOLYSIN(R) in combination with a standard dosage of paclitaxel and carboplatin.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin. Secondary objectives include the evaluation of immune response to th
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
2. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
3. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
4. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
5. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
6. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
7. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
8. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
11. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Cytochroma today announced that it has appointed John Cunningham, ... Advisory Board. , Dr. Cunningham is Professor of Nephrology ... at the Royal Free Hospital, London. His early training ... in The University of London and Washington University ...
... , SLINGERLANDS, N.Y., Oct. 15 Sabre Technical Services ... to the problems experienced by U.S. homeowners and builders ... Sabre,s solution is an adaptation of its patented chlorine ... and smaller buildings. , Sabre has a long history ...
... ... Inc. announced that it completed its pre-IND meeting with the U.S. Food ... evaluate the safety and efficacy of Stemedica,s high potency proprietary allogeneic mesenchymal ... Based on a meeting October 13, 2009 with the FDA, Stemedica is ...
Cached Biology Technology:Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board 2Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board 3Sabre Announces Roll-Out of Permanent Solution to Chinese Drywall Problems 2Sabre Announces Roll-Out of Permanent Solution to Chinese Drywall Problems 3Stemedica Completes Meeting with the FDA 2Stemedica Completes Meeting with the FDA 3
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... and other senior female family members should play a key ... in non-Western societies. However, they are often overlooked by health ... see them as an obstacle to promoting good nutrition and ... extensive literature review published in the January issue of ...
... celebrates its 50,000th eBook, available on its online ... Springer,s position as the largest eBook publisher and ... comprehensive online collection of science, technology and medicine ... addition, as announced in October 2011, Springer will ...
... may soon benefit from an experimental drug being tested by ... Texas A&M College of Veterinary Medicine & Biomedical Sciences ... similar injuries. Funded through a three-year, $750,000 grant from ... has already proven effective in mice at UCSF. Now the ...
Cached Biology News:Research highlights key role grandmothers play in mother and child nutrition and health 2Research highlights key role grandmothers play in mother and child nutrition and health 3SpringerLink now offers more than 50,000 eBooks 2Saving dogs with spinal cord injuries 2
BAI-1 (T-20)...
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... peptide derived from the N-terminal region of ... Specificity: Specific for the N-terminus of the ... Dog Rat Mouse (positive controls: MDCK-II A431 ... heart blood vessel and brain mossy fiber ...
Biology Products: